Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

PhRMA Launches New Ad Campaign to Improve Biopharma’s Image

XTALKS VITALS NEWS

Advertising

The ads will be featured on multiple media streams – including TV, print and digital – in an effort to repair the industry’s tarnished reputation after highly-publicized enquiries into drug price hikes.

Share this!

January 26, 2017 | by Sarah Hand, M.Sc.

Pharmaceutical industry trade group, PhRMA, has unveiled a new multimillion-dollar ad campaign named GoBoldly. The ads will be featured on multiple media streams – including TV, print and digital – in an effort to repair the industry’s tarnished reputation after highly-publicized enquiries into drug price hikes.

“Thanks to the tireless work of biopharmaceutical researchers and scientists, we have entered a new era of medicine that is transforming the way we prevent and treat disease,” said Stephen J. Ubl, president and chief executive officer of PhRMA. “This campaign spotlights their perseverance and unwavering commitment to American patients for whom we all work. We will also be convening events with stakeholders all across the country to discuss ways we can work together to make our health care system more responsive to the needs of patients.”

The first GoBoldy ad – “Do Not Go Gentle” – features video of scientists at work compiled with images of cells and blood flowing through vessels. The ad also includes Dylan Thomas’ poem of the same name being read aloud over the images and video.



In response to an ad campaign Ubl is calling, “less hoodie, more lab coats,” ex-pharma CEO Martin Shkreli created a website aimed at airing some of the industry’s dirty laundry. Pharmaskeletons.com names 26 pharma companies and how they’ve negatively contributed to the current state of drug pricing in the US.

In a few weeks, the trade organization will release their next ad – “Cells” – which reportedly shows video of a cancer cell self-destructing. The new ad campaign sends a stronger message compared to PhRMA’s previous emotionally-driven “From Hope to Cures” campaign.

However, this new attempt by the industry to improve public relations makes no mention of changing the pricing practices which have become such a hot-button issue in the industry today. Instead the multiyear campaign will focus on the most exciting new advancements in science and medicine, value-driven healthcare and public health matters.


Keywords: Advertising, Biopharma, Pharmaceutical Industry


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Amgen Identifies Issue with Patient Access to PCSK9 Inhibitor

March 23, 2017 - Most US patients hoping to get their PCSK9 inhibitor medications covered by their prescription drug plan are being denied, according to two new studied conducted by Amgen.

Featured In: Biotech News


Smartphone App Created Using Apple’s ResearchKit Used to Conduct Asthma Clinical Studies

March 22, 2017 - Researchers at the Icahn School of Medicine at Mount Sinai have conducted a large-scale, observational study of asthma patients using the Apple ResearchKit framework and the Asthma Health app on patients’ iPhones.

Featured In: Clinical Trials News


IBS Patients Taking Viberzi May Be at Increased Risk of Pancreatitis

March 22, 2017 - According to a recent drug safety communication issued by the US Food and Drug Administration (FDA), patients with irritable bowel syndrome (IBS) with diarrhea should not be treated using Viberzi (eluxadoline), if they do not have a gallbladder.

Featured In: Drug Safety News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.